BioSpace News Archive

Sarepta Therapeutics, Inc. today announced that screening is underway in Study SRP-9003-301.

PRP Dosing & Method to Treat Cancer Stem Cells Patents Validated in Countries Across Europe Resulting in Growing IP Portfolio of 87 patents.

Lexaria Bioscience Corp. announces a comprehensive planned applied research program to thoroughly evaluate DehydraTECH for the improved delivery of GLP-1 drugs, designed to support prospective commercial partnering with the global pharmaceutical companies.

Kairos Pharma, Ltd. announces the dosing of its first two patients in its Phase 1 trial testing a combination therapy for its lead therapeutic candidate ENV105 in combination with osimertinib for the treatment of non-small cell lung cancer.

Promega research published today in Nature Communications demonstrates a new potential approach for managing multiple myeloma and other hematological cancers.

Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to PTX-252 for the treatment of Acute Myeloid Leukaemia (AML).

Glaucoma Research Foundation (GRF) will host the 13th Annual Glaucoma 360 New Horizons Forum on February 9th at San Francisco’s historic Westin St. Francis Hotel.

Merit Medical Systems, Inc. (NASDAQ: MMSI) today announced the successful enrollment of the first patient in its multicenter, prospective, randomized, controlled trial comparing genicular artery embolization (GAE) using Embosphere® Microspheres to corticosteroid injections for the treatment of symptomatic knee osteoarthritis (MOTION) study.

Ascentage Pharma announced that olverembatinib has been included in the latest guidelines from the National Comprehensive Cancer Network for the management of Chronic Myeloid Leukemia,[1] marking a major development in global recognition for its best-in-class drug candidate, which has been approved in China for the management of tyrosine kinase inhibitor -resistant patients with chronic- and accelerated-phase CML.

PolTREG S.A. announced it received a Notice of Allowance from the United States Patent and Trademark Office, covering the manufacturing of T-regulatory cells to treat Type-1 Diabetes, and ways the therapy is administered.